On Our Radar

• 举报此文章

Jonathan Usuka

Jonathan Usuka

CxO | Ex-McKinsey | PE Advisor | Pharma AI

发布日期: 2020年12月18日

+ 关注

It’s not all about oncology (Part 3 - Hemophilia).

Following on BioMarin’s setbacks with a hemophilia gene therapy earlier this year, Novo invests in a spin out with experienced, home grown drug hunters and a bispecific antibody platform that produced spectacular results in Multiple Myeloma through Darzalex. 

要查看或添加评论，请登录

Jonathan Usuka的更多文章

• How Data and Real World Evidence are Shaping the Future of Discovery and Development

  2021年9月24日

  How Data and Real World Evidence are Shaping the Future of Discovery and Development

  Looking forward to NEW YORK BIO's annual meeting on Monday! IBM Watson Health's Lorraine Marchand will be leading a…

  18
• Welcoming Chuck Ryan to lead the Prostate Cancer Foundation!

  2021年8月26日

  Welcoming Chuck Ryan to lead the Prostate Cancer Foundation!

  Dr. Ryan is an internationally recognized genitourinary oncologist with expertise in the biology and treatment of…

  4
• Pancreatic cancer is one of the deadliest cancers - we are creating an integrated diagnostics platform to help change that.

  2021年8月19日

  Pancreatic cancer is one of the deadliest cancers - we are creating an integrated diagnostics platform to help change that.

  According to the American Cancer Society, pancreatic cancer is one of the deadliest cancers, with a 5-year survival…

  29

  1 条评论
• New chapter in the journey...

  2021年8月12日

  New chapter in the journey...

  After an amazing 6 years at McKinsey, this week I am beginning a new chapter in my lifelong journey of helping patients…

  257

  72 条评论
• On our radar: Calyx

  2021年2月1日

  On our radar: Calyx

  Paraxel spins out imaging and informatics Focusing on industry leading imaging capabilities, especially in oncology, as…

  2
• DoubleClick on Diagnostics: San Diego

  2021年1月29日

  DoubleClick on Diagnostics: San Diego

  Eight years after the acquisition of Life Technologies, Thermo demonstrated sustained commitment to expansion in…

  5
• DoubleClick on Discovery: San Diego

  2021年1月27日

  DoubleClick on Discovery: San Diego

  Excellent introduction of the protein degradation technology as described by a Celgene San Diego colleague:

  7

  1 条评论
• DoubleClick on Discovery: San Diego

  2021年1月25日

  DoubleClick on Discovery: San Diego

  As targeted protein degradation continues to show promise, San Diego startup Plexium closes a substantial raise from…

  3
• On Our Radar

  2021年1月22日

  On Our Radar

  Integrating AI in discovery and development AI players in R&D work within the pharma “silos,” because these functions…

  2
• On Our Radar: Gene editing

  2021年1月20日

  On Our Radar: Gene editing

  There is profound promise for treating disease by editing a patient’s individual genome. But some potential limitations…

  6

Show more

See all articles